Sector News

What do millennials and boomers have in common? Healthcare consumer behaviors, it turns out

November 7, 2021
Life sciences

When it comes to how consumers seek and consume healthcare information, the generational divide between Generation Z, millennials and boomers may not be as wide as you’d think.

That’s according to CMI Media Group’s latest Media Vitals annual report, which bucks some of the conventional wisdom about how to market healthcare products to different age groups. The report, based on an online survey of 2,000 consumers, examined what healthcare consumers want and need from life science manufacturers.

The upshot for pharma marketers? Don’t rely on outdated assumptions, Brian Wagner, CMI’s vice president for product development, said in an interview.

“I’m not saying a senior boomer is going to be just like a Gen Z and vice versa,” he said. “But we’re seeing that generational gap getting smaller.”

For example, one common stereotype is that seniors aren’t digitally savvy. But Wagner said the pandemic pushed many older adults to quickly learn new technology, like how to stream a movie on Netflix or navigate a telehealth visit with their doctor.

So, instead of discounting digital platforms as a way to reach them, pharma marketers should try to understand their individual preferences, Wagner said.

“As a 55-year-old GenXer, you’re not going to find me anytime soon sitting on my couch watching a movie on this,” he said, holding up his smartphone. “But the fact that I can use Alexa to access my Pandora app to get good dinner music, that’s something else.”

Consumers, regardless of age, are putting more trust in health websites like WebMD than they have in the past, the report found. Of particular note to pharma companies, branded websites saw the biggest trust gains across all age groups, and especially among millennials, nearly half of whom cited brand sites as a “trusted source.”

Wagner credited the pandemic for raising the profile of the industry and health agencies like the Centers for Disease Control and Prevention and the FDA. “They’re part of our normal dinner table conversation,” he said.

The doctor’s office, nonetheless, remains the go-to source for health information across all age groups. It was cited by 42% of millennials (ages 25-40) and 50% of baby boomers (ages 57-75). Email is the second choice for both groups, at 28% and 37%, respectively.

The difference, though, is that older consumers are more likely to say they follow their doctors’ orders (69% for people over 75 versus 33% of 18- to 24-year-olds). Younger patients are more likely to supplement information they get from HCPs with their own research.

While the report found only 3% of boomers want to get their healthcare information from social media (compared to 28% of Gen Z and and 21% of millennials), it suggests drugmakers shouldn’t ignore places like Twitter and Facebook when targeting older consumers.

Given the sheer size of that age group, that can still be a lot of eyes on ads, the report points out.

by Natalie Missakian

Source: fiercepharma.com

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach